Get started
Outlook Therapeutics, Inc.Outlook Therapeutics, Inc.Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

OTLK chart


Full chart

Key facts today


Outlook Therapeutics has a PDUFA date of August 27, 2025, for the FDA's decision on ONS-5010, a treatment for wet AMD, backed by NORSE EIGHT trial data.
Analyze the impactAnalyze the impact

OTLK upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪56.92 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.14 USD
Net income (FY)
‪−75.37 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪20.52 M‬
Beta (1Y)
0.50

Employees


Employees (FY)
23
Change (1Y)
−1 −4.17%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−3.28 M‬ USD

About Outlook Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Lawrence A. Kenyon
Website
outlooktherapeutics.com
Headquarters
Iselin
Founded
2010
FIGI
BBG00469JRJ5
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

OTLK news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as OTLK.

Frequently Asked Questions


The current price of OTLK is 1.68 USD — it has decreased by −6.01% in the past 24 hours. Watch Outlook Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Outlook Therapeutics, Inc. stocks are traded under the ticker OTLK.
OTLK stock has risen by 16.32% compared to the previous week, the month change is a 16.32% rise, over the last year Outlook Therapeutics, Inc. has showed a −77.55% decrease.
We've gathered analysts' opinions on Outlook Therapeutics, Inc. future price: according to them, OTLK price has a max estimate of 24.00 USD and a min estimate of 3.00 USD. Watch OTLK chart and read a more detailed Outlook Therapeutics, Inc. stock forecast: see what analysts think of Outlook Therapeutics, Inc. and suggest that you do with its stocks.
OTLK reached its all-time high on Sep 1, 2016 with the price of 878.40 USD, and its all-time low was 0.87 USD and was reached on Nov 27, 2024. View more price dynamics on OTLK chart.
See other stocks reaching their highest and lowest prices.
OTLK stock is 10.49% volatile and has beta coefficient of 0.50. Track Outlook Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Outlook Therapeutics, Inc. there?
Today Outlook Therapeutics, Inc. has the market capitalization of ‪54.64 M‬, it has increased by 43.97% over the last week.
Yes, you can track Outlook Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Outlook Therapeutics, Inc. is going to release the next earnings report on Aug 13, 2025. Keep track of upcoming events with our Earnings Calendar.
OTLK earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.54 USD resulting in a 26.31% surprise. The estimated earnings for the next quarter are −0.44 USD per share. See more details about Outlook Therapeutics, Inc. earnings.
Outlook Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪628.25 K‬ USD. In the next quarter, revenue is expected to reach ‪1.57 M‬ USD.
OTLK net income for the last quarter is ‪17.38 M‬ USD, while the quarter before that showed ‪5.69 M‬ USD of net income which accounts for 205.34% change. Track more Outlook Therapeutics, Inc. financial stats to get the full picture.
No, OTLK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 16, 2025, the company has 23 employees. See our rating of the largest employees — is Outlook Therapeutics, Inc. on this list?
Like other stocks, OTLK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Outlook Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Outlook Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Outlook Therapeutics, Inc. stock shows the sell signal. See more of Outlook Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.